Schadendorf, D; Ugurel, S; Schuler-Thurner, B; Nestle, FO; Enk, A; Brocker, EB; Grabbe, S; Rittgen, W; Edler, L; Sucker, A; Zimpfer-Rechner, C; Berger, T; Kamarashev, J; Burg, G; Jonuleit, H; Tuttenberg, A; Becker, JC; Keikavoussi, P; Kampgen, E; Schuler, G.
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Ann Oncol. 2006; 17(4):563-570
Doi: 10.1093/annonc/mdj138
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar